260 related articles for article (PubMed ID: 24296883)
21. FDG PET/CT Findings of the Recurrent Posttransplantation Lymphoproliferative Disorder in a Pediatric Liver Transplant Recipient With Right Leg Pain as the Only Complaint.
Bai X; Yang H; Zhuang H
Clin Nucl Med; 2015 Oct; 40(10):832-4. PubMed ID: 26098286
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic performances of F-18 FDG PET or PET/CT for detection of post-transplant lymphoproliferative disorder: a systematic review and meta-analysis.
Kim DH; Kim SJ
Nucl Med Commun; 2020 Jun; 41(6):533-539. PubMed ID: 32282633
[TBL] [Abstract][Full Text] [Related]
23.
Song H; Guja KE; Iagaru A
Semin Nucl Med; 2021 Jul; 51(4):392-403. PubMed ID: 33455722
[TBL] [Abstract][Full Text] [Related]
24. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and management roles of FDG PET/CT imaging in post-transplant lympho-proliferation in pediatric heart transplantation.
Brown AK; Carapellucci J; Oshrine B; Gomez A; Meoded A; Asante-Korang A
Clin Transplant; 2023 Sep; 37(9):e15015. PubMed ID: 37237443
[TBL] [Abstract][Full Text] [Related]
26. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
Watanabe S; Manabe O; Hirata K; Oyama-Manabe N; Hattori N; Kikuchi Y; Kobayashi K; Toyonaga T; Tamaki N
BMC Cancer; 2016 Aug; 16():635. PubMed ID: 27528380
[TBL] [Abstract][Full Text] [Related]
27. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
28. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
[TBL] [Abstract][Full Text] [Related]
29. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
Zimmermann H; Denecke T; Dreyling MH; Franzius C; Reinke P; Subklewe M; Amthauer H; Kneba M; Riess H; Trappe RU
Transplantation; 2018 May; 102(5):868-875. PubMed ID: 29189632
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial.
Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC
Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379
[TBL] [Abstract][Full Text] [Related]
31. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
32. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
33. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
[TBL] [Abstract][Full Text] [Related]
34. The impact of (18)F-FDG-PET/CT on Merkel cell carcinoma management: a retrospective study of 66 scans from a single institution.
George A; Girault S; Testard A; Delva R; Soulié P; Couturier OF; Morel O
Nucl Med Commun; 2014 Mar; 35(3):282-90. PubMed ID: 24240193
[TBL] [Abstract][Full Text] [Related]
35. Posttransplantation lymphoproliferative disorder of the abdomen: CT evaluation in 51 patients.
Pickhardt PJ; Siegel MJ
Radiology; 1999 Oct; 213(1):73-8. PubMed ID: 10540643
[TBL] [Abstract][Full Text] [Related]
36. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
37. The role of
Wang C; Wang G; Wang W; Kan Y; Zhang M; Yang J
Quant Imaging Med Surg; 2024 Feb; 14(2):1323-1334. PubMed ID: 38415126
[TBL] [Abstract][Full Text] [Related]
38. Is (18)F-FDG-PET/CT prognostic factor for survival in patients with small cell lung cancer? Single center experience.
Inal A; Kucukoner M; Kaplan MA; Urakci Z; Nas N; Guven M; Dostbil Z; Altindag S; Isikdogan A
Rev Port Pneumol; 2013; 19(6):260-5. PubMed ID: 23993406
[TBL] [Abstract][Full Text] [Related]
39. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
Salem SS; Shahin MA
Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
[TBL] [Abstract][Full Text] [Related]
40. Myelofibrosis on 18F-FDG-PET/CT in a case suspicious for post-transplant lymphoproliferative disorder.
Khanna V; Nama S; Tailor R; Muthukrishnan A
Hell J Nucl Med; 2009; 12(3):274-5. PubMed ID: 19936343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
